ID
14945
Descrizione
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either pneumococcal vaccine or Prevenar™ in study 105553. Antibody persistence will be evaluated at 8-14 mo after completion of the 3-dose immunization course in study 105553. The immune response to a booster dose of GSK Biologicals' pneumococcal conjugate vaccine will also be evaluated when given at 12-18 mo to subjects not primed with GSK Biologicals' vaccine but with Prevenar™. The study has 3 groups. 1 group of children primed with GSK Biologicals' pneumococcal conjugate vaccine will receive a booster dose of the same vaccine. 2nd group of children primed with Prevenar™ will receive a booster dose of Prevenar™ (control group). 3rd group of children primed with Prevenar™ will receive a booster dose of GSK Biologicals' pneumococcal conjugate vaccine. All children will receive concomitantly a booster dose of DTPa-HBV-IPV/Hib vaccine. NCT00370396 Part: Study Conclusion
Keywords
versioni (2)
- 09/05/16 09/05/16 -
- 11/05/16 11/05/16 -
Caricato su
9 maggio 2016
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Study Conclusion "Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine" NCT00370396
Study Conclusion "Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine" NCT00370396
Descrizione
Study Conclusion
Descrizione
If yes, select major reason for withdrawal.
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C2349954
Descrizione
If Serious adverse event: --> Please complete and submit SAE report --> Please specify SAE No. If Non-Serious adverse event: --> Please complete Non-serious Adverse Event section --> Please specify AE No. or solicited AE code If Other, please specify:
Tipo di dati
text
Alias
- UMLS CUI [1,1]
- C2349954
- UMLS CUI [1,2]
- C0392360
Descrizione
SAE No
Tipo di dati
text
Alias
- UMLS CUI [1]
- C1519255
Descrizione
AE No or solicited AE No
Tipo di dati
text
Alias
- UMLS CUI [1]
- C0877248
Descrizione
in case of Protocol violation specify here
Tipo di dati
text
Alias
- UMLS CUI [1]
- C1709750
Descrizione
Other, specification
Tipo di dati
text
Alias
- UMLS CUI [1]
- C2348235
Descrizione
Who made the decision
Tipo di dati
text
Alias
- UMLS CUI [1]
- C1389424
Descrizione
Date of last contact
Tipo di dati
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C1705415
Descrizione
If no, please give details in Adverse Events section.
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C0012634
Descrizione
Investigators Signature
Alias
- UMLS CUI-1
- C1519316
Similar models
Study Conclusion "Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine" NCT00370396
C0805701 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C1705415 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])